Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC

Ying, Hou-Qun; Liao, Yu-Cui; Luo, Yan-Ran; Xiong, Gang; Huang, Ying; Nie, Ruo-Wei; Xiong, Cui-Fen; Cheng, Xue-Xin

doi:10.1016/j.phrs.2021.105734

Cited by 10 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, many prognostic biomarkers are used to evaluate a variety of malignant tumors, such as AFR, fibrinogen-to-prealbumin (FPR), neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio. [23][24][25][26] However, the diagnostic value of these markers for Hp-NGC remains unclear. Therefore, this study explored the clinical value of PFR and AFR in the diagnosis of Hp-NGC.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer

Zhang

Qin

et al. 2022

Int J Biol Markers

View full text Add to dashboard Cite

Background This study aimed to investigate the diagnostic value of prealbumin-to-fibrinogen ratio (PFR) and albumin-to-fibrinogen ratio (AFR) alone or in combination in Helicobacter pylori-negative gastric cancer (Hp-NGC) patients. Methods This study included 171 healthy controls, 180 Hp-NGC patients, and 215 Helicobacter pylori-negative chronic gastritis (HpN) patients. We compared the differences of various indicators and pathological characteristics between groups with Mann–Whitney U test and Chi-square test. The diagnostic value of PFR and AFR alone or in combination for Hp-NGC patients was assessed by the receiver operating characteristic (ROC) curve. Results PFR and AFR were related to the progression and clinicopathological characteristics of Hp-NGC. As the disease progressed, PFR and AFR values gradually decreased and were negatively related to the tumor size and depth of invasion. In addition, the area under the curves (AUCs) that resulted from combining PFR and AFR to distinguish Hp-NGC patients from healthy controls and HpN patients were 0.908 and 0.654, respectively. When combined with PFR and AFR in the differential diagnosis of tumors with a maximum diameter ≥ 5 cm and the T3 + T4 stage, the AUCs were 0.949 and 0.922; the sensitivity was 86.32% and 80.74%; and the specificity was 94.74% and 92.98%, respectively. Conclusions PFR and AFR may be used as diagnostic biomarkers for Hp-NGC. The combination of PFR and AFR was more valuable than each indicator alone in the diagnosis of Hp-NGC.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer

Zhang

Qin

et al. 2022

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

“…Compared with other existing indexes based on inflammation, such as NLR, PLR, and LMR, SII was a more comprehensive and reliable indicator which had more value in predicting OS than other indices in this study. The prognostic role of SII has been demonstrated in patients with NSCLC, including NSCLC patients with BM harboring EGFR mutations and patients receiving treatment with EGFR-TKIs, and elevated SII values indicated a worse OS [ 29 , 30 ]. Because of the tight correlation between radiotherapy and immune status, we hypothesized that SII may be related to the efficacy of radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy

et al. 2022

View full text Add to dashboard Cite

Background The systemic immune-inflammation index (SII) has recently emerged as a predictor of survival in non-small cell lung cancer patients. There is also tight correlation between radiotherapy and immune status, and brain metastases (BM) radiotherapy is an important treatment in patients with BM from lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations. Hence, this study aimed to present the prognostic value of SII and its dynamic changes during BM radiotherapy in EGFR-mutant lung adenocarcinoma patients with BM. Methods Patients with EGFR-mutant lung adenocarcinoma who received BM radiotherapy between November 2011 and April 2021 were included in this retrospective study. The SII was calculated using data acquired within 1 week before the start of radiation treatment and 1 week before its completion. According to the cutoff value of SII before radiation treatment determined using receiver operating characteristic curve analyses, we divided the patients into a high group and a low group. Patients were further classified into high–high, high–low, low–low, and low–high groups based on dynamic changes in SII. Prognostic values of the SII and other factors were determined using the Kaplan–Meier method, as well as univariate and multivariate Cox analysis. Results A total of 202 patients met the inclusion criteria, and the median overall survival (OS) of the entire cohort was 36 months. According to the SII cutoff of 859.79, an SII value below this cutoff was associated with longer OS (hazard ratio 0.6653, 95% confidence interval 0.4708–0.9402, P < 0.05). The patients in the low–low group, whose SII within 1 week before the start and end of BM radiotherapy were below the cutoff, had a median OS of 55.2 months, which was significantly longer than the OS in all other groups (P < 0.05). Univariate and multivariate analyses confirmed that dynamic SII change (P = 0.032), Lung-molGPA (P < 0.001), and thoracic radiation (P = 0.048) were independently correlated with OS. Conclusions The SII and its dynamic change may have a prognostic value in patients with EGFR-mutant lung adenocarcinoma treated with BM radiotherapy.

show abstract

“…Additionally, as a major environmental factor causing carcinogenesis and metastasis of NSCLC, cancer-associated inflammation and the inflammatory biomarker forecasting the clinical efficacy of TKIs and prognosis of NSCLC patients also need to be paid attention ( 14 ). Although only 20% of cancers are connected with chronic inflammation, innate immune cells and mediators are used to involve in most human malignancies ( 15 , 16 ).…”

Section: Introductionmentioning

confidence: 99%

Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer

Yang

Huang

Zhao³

2022

Front. Immunol.

View full text Add to dashboard Cite

Lung cancer remains one of the most common malignancies in the world. Nowadays, the most common lung cancer is non-small cell lung cancer (NSCLC), namely, adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Epigenetic alterations that refer to DNA methylation, histone modifications, and noncoding RNA expression, are now suggested to drive the genesis and development of NSCLC. Additionally, inflammation-related tumorigenesis also plays a vital role in cancer research and efforts have been attempted to reverse such condition. During the occurrence and development of inflammatory diseases, the immune component of inflammation may cause epigenetic changes, but it is not always certain whether the immune component itself or the stimulated host cells cause epigenetic changes. Moreover, the links between epigenetic alterations and cancer-related inflammation and their influences on the human cancer are not clear so far. Therefore, the connection between epigenetic drivers, inflammation, and NSCLC will be summarized. Investigation on such topic is most likely to shed light on the molecular and immunological mechanisms of epigenetic and inflammatory factors and promote the application of epigenetics in the innovative diagnostic and therapeutic strategies for NSCLC.

show abstract

Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC

Cited by 10 publications

References 37 publications

Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer

Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer

Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy

Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About